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Abstract. Granic A, Aspray T, Hill T, Davies K,
Collerton J, Martin-Ruiz C, von Zglinicki T,
Kirkwood TBL, Mathers JC, Jagger C (Institute for
Ageing and Health, Newcastle University,
Newcastle upon Tyne; Human Nutrition Research
Centre, Newcastle University, Newcastle upon
Tyne, and School of Agriculture, Food and Rural
Development, Newcastle University, Newcastle
upon Tyne, UK). 25-hydroxyvitamin D and
increased all-cause mortality in very old women:
the Newcastle 85+ study. J Intern Med 2015; 277:
456–467.
Objective. To investigate the associations between low
and high concentrations of baseline serum 25-
hydroxyvitamin D [25(OH)D] and all-cause mortal-
ity in very old (≥85 years) men and women over
6 years.
Design, setting and subjects. Prospective mortality data
from 775 participants in the Newcastle 85+ Study
were analysed for survival in relation to 25(OH)D
(season-specific quartiles and predefined cut-off
values) and sex using Cox proportional hazards
models. The models were fitted to the entire and
restricted (nonusers of vitamin D-containing sup-
plements and medication) cohorts.
Results. For the entire cohort, mortality was higher in
both the lowest and highest 25(OH)D season-
specific quartiles [SQ1: hazard ratio (HR) 1.31,
95% confidence interval (CI) 1.01–1.69, P = 0.04;
SQ4: HR 1.44, 95% CI 1.12–1.85, P = 0.004] com-
pared with the combined middle quartiles
(SQ2 + SQ3), after adjustment for sociodemo-
graphic factors. The increased risk for the highest
quartile remained significant after further adjust-
ment for lifestyle variables (SQ4: HR 1.37, 95% CI
1.06–1.77, P = 0.02) and was seen only in women
in sex-specific analyses. Similarly, in sensitivity
analyses with predefined 25(OH)D cut-off values,
the highest 25(OH)D concentration (≥75 nmol L1)
was associated with a 2.4-fold increased risk of
mortality in women (restricted cohort) after adjust-
ing for all covariates.
Conclusion. Low and high season-specific 25(OH)D
quartiles were associated with increased risks of
mortality over 6 years in the very old; this effect
was particularly noticeable in women, including
those who reported taking vitamin D-containing
supplements/medication.
Keywords: ageing, cohort study, mortality, risk fac-
tor, vitamins, women’s health.
Introduction
In the past two decades, accumulated evidence
from cellular, animal and population-based stud-
ies has indicated the involvement of vitamin D
metabolites in immunomodulation, cancer inhibi-
tion and cardiovascular, respiratory, brain and
muscle function [1–5]. These extra-skeletal effects
of vitamin D suggest its potential role in overall
health and survival [6]. Recent observational stud-
ies in the general and older populations (≥65) have
shown a non-linear relationship between serum
hydroxyvitamin D [25(OH)D], the major circulatory
and storage form of vitamin D, and both
disease-specific and all-cause mortality [7–12].
This indicates that moderate rather than low or
high concentrations of 25(OH)D may result in more
favourable health outcomes and increased sur-
vival. Using an evidence-based approach for bone
health, the US Institute of Medicine (IOM) has
produced its latest report stating that: (i) concen-
trations of 50 nmol L1 (20 ng mL1) 25(OH)D
meet the requirements of 97.5% of the North
American population; (ii) concentrations of
≥75 nmol L1 (30 ng mL1) are not consistently
associated with increased health benefits; and (iii)
not all persons have inadequate 25(OH)D if con-
centrations are below 50 nmol L1 [13]. Amongst
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at-risk groups, older adults are more likely to have
lower 25(OH)D levels [14–16] because of reduced
skin 7-dehydrocholesterol concentrations (the
cutaneous precursor of vitamin D), inefficient renal
activation of 25(OH)D and a reduction in outdoor
activities with advancing age [17]. These factors
also contribute to greater variability in both serum
25(OH)D concentrations and in the average
requirement for vitamin D supplementation in
older adults [13, 18]. The findings of observational
studies, randomized control trials (RCTs) and ben-
efit–risk assessments all suggest that vitamin D
supplementation in the general and older popula-
tions can ameliorate suboptimal 25(OH)D concen-
trations without adverse effects on disease-specific
or all-cause mortality [19–24].
However, there is no agreement amongst research-
ers and healthcare professionals about the opti-
mal, beneficial and age-specific 25(OH)D
concentrations in relation to extra-skeletal out-
comes and mortality [13, 17, 18, 25, 26], especially
in older adults. Current evidence supports an
inverse or non-linear association between 25(OH)
D levels and mortality amongst adults aged
65 years and older. For example, a recent meta-
analysis including 24 000 participants from nine
prospective observational studies demonstrated a
25% increased pooled hazard ratio for all-cause
mortality in the lowest compared with the highest
25(OH)D category in those aged ≥65 years [27]. A
similar meta-analysis which included 12 studies
(30 000 participants) confirmed an inverse associ-
ation between 25(OH)D and mortality and a
decrease in mortality risk of 8% for an increase in
25(OH)D of 20 nmol L1 [28]. Two recent popula-
tion-based studies from Denmark [10] and Israel
[11], which both included over 40% of older adults
(aged ≥65 years), showed a reversed J- and
U-shaped relationship between 25(OH)D concen-
tration and total mortality, respectively, and the
best survival for individuals with 25(OH)D levels
between 50 and 90 nmol L1. Similarly, an exam-
ination of the National Health and Nutrition Exam-
ination Survey (NHANES) data (2001–2004)
revealed no significant reduction in mortality above
21 ng mL1 (52.6 nmol L1) 25(OH)D [9].
To our knowledge, no prospective cohort study has
investigated the relationship between 25(OH)D and
mortality in the very old (aged ≥85 years), despite
this being the fastest growing segment of many
populations worldwide. Furthermore, except for
the study conducted amongst members of the
Clalit Health Services in Israel [11], the numbers
of very old adults included in the above-mentioned
studies were small. We therefore used data from
the Newcastle 85+ Study to assess the relationship
between serum 25(OH)D and all-cause mortality
over 6 years in this elderly population.
Methods
Study sample
Participants were members of the Newcastle 85+
Study, a prospective study of health trajectories in
a 1921 birth cohort recruited at the age of 85
through general practices in Newcastle and North
Tyneside, UK. The study design has been described
in detail elsewhere [29, 30]. Briefly, a health
assessment (comprising questionnaires, measure-
ments, function tests and a fasting blood sample)
was carried out in each participant’s usual resi-
dence, including institutions, by a research nurse.
General practice medical records were reviewed for
diagnosed diseases, consultations and prescribed
medication. At baseline in 2006/2007, both health
assessment and general practice records data were
available for 845 participants (58.2% of those
eligible to participate) and general practice record
review only for a further 188. The representative-
ness of the 845 eligible individuals with respect to
the population of England and Wales of the same
age has been reported [30]. Fasting blood samples
were collected between July 2006 and September
2007 for 778 participants, and were sent within
1 h to the clinical biochemistry laboratory at
the Royal Victoria Infirmary, Newcastle, UK for
analyses.
Ethics
The study was approved by the Newcastle & North
Tyneside Local Research Committee One.
Mortality data
Dates of death were obtained through the Health
and Social Care Information Service UK. Survival
time (in years) was calculated from the date of
blood collection to the date of death or of censoring
on 1 April 2012.
Serum 25(OH)D assay and categorization
Serum 25(OH)D was measured with a radioimmu-
noassay kit (DiaSorin Corporation, Stillwater, MN,
USA) using 25(OH)D-specific antibodies and
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125I-labelled 25(OH)D as a tracer, as previously
described [31]. The working range of the assay
was 6–250 nmol L1 and the interassay coeffi-
cients of variation were 8.4% and 12.6% at 25
(OH)D concentrations of 39.4 nmol L1 and
133.5 nmol L1, respectively. In 775 (99.6%) par-
ticipants, 25(OH)D concentrations were success-
fully measured at baseline and were categorized
into season-specific quartiles (SQ1–SQ4) as shown
in Table S1. Briefly, SQ1 ranged from 5–
17 nmol L1 (spring) to 8–30 nmol L1 (autumn);
SQ2 ranged from 18–26 nmol L1 (spring) to 29–
45 nmol L1 (summer); SQ3 ranged from 27–
46 nmol L1 (spring) to 46–68 nmol L1 (summer);
and SQ4 ranged from ≥47 nmol L1 (spring) to
≥69 nmol L1 (summer). The middle quartiles (SQ2
and SQ3) were combined and used as the referent,
thus forming three season-specific 25(OH)D
groups: lowest (SQ1), middle (SQ2 + SQ3) and
highest (SQ4). The dates of blood collection were
categorized into winter (December–February),
spring (March–May), summer (June–August) and
autumn (September–November), and used to con-
trol for seasonal variation in 25(OH)D concentra-
tion in analyses with predefined 25(OH)D cut-off
values (see below).
Other measures and confounders
Confounders commonly used in studies investigat-
ing mortality risk in relation to 25(OH)D were
considered for inclusion in models [7–12]. A
detailed description of each confounder can be
found in Table S2. Briefly, sociodemographic fac-
tors (sex, education, marital status and number of
sources of income), lifestyle factors (smoking,
alcohol intake and physical activity), morbidity
(number of chronic diseases, waist–hip ratio and
renal impairment) and mental health variables
(global cognitive impairment assessed by the 30-
point Standardized Mini Mental Status Examina-
tion (SMMSE) and depressive symptoms assessed
by the 15-item Geriatric Depression Scale) were
included in the models. The analyses were con-
ducted for the entire cohort with available 25(OH)D
data, and subsequently stratified by sex. We con-
sidered the intake of vitamin D-containing supple-
ments and prescribed medication as important
biological determinants of 25(OH)D status in this
population [23, 24] and conducted separate analy-
ses with a restricted cohort [i.e. excluding 150
(19.4%) individuals who were taking vitamin D
supplements/medication] with and without strat-
ification by sex. Because of a low proportion of
missing values (≤5%), confounders with missing
data were imputed based on the mean (i.e. waist–
hip ratio) or referent category (e.g. education or
depressive symptoms). We used multiple linear
regression to assess the confounders for multicol-
linearity and by inspecting VIF tolerance, eigen-
values and the condition index.
Statistical analysis
The characteristics of participants who died before
1 April 2012 and those who survived thereafter
were compared using independent t-tests and
Mann–Whitney and chi-squared tests for continu-
ous, ordered and categorical variables, respec-
tively. We also compared those who had missing
25(OH)D data with those for whom 25(OH)D data
were available. The Kaplan–Meier test was used to
assess the relative risk of mortality by 25(OH)D
categories in the entire and restricted cohorts and
separately by sex. The time interval was calcu-
lated as period between the date of blood collec-
tion and the date of death or 1 April 2012. The
Kaplan–Meier plots were inspected for proportion-
ality of risk in relation to 25(OH)D categories over
6 years.
Cox proportional hazards models were employed to
explore the relative risk of mortality associated
with the season-specific 25(OH)D group across
four models, adjusting for potential mortality-
and vitamin D-related confounders. Log-minus-
log plots were inspected for violation of the
proportionality-of-hazard assumption by 25(OH)D
group during follow-up. We estimated hazard
ratios (HRs) with 95% confidence intervals (CIs)
as: (i) unadjusted (Model 1); (ii) adjusted for soci-
odemographic variables (sex, education, marital
status and income; Model 2); (iii) additionally
adjusted for lifestyle factors (smoking, alcohol
intake and physical activity; Model 3); and (iv)
further adjusted for mental health and morbidity-
related variables [cognitive impairment (≤25 points
on the SMMSE scale), depressive symptoms, num-
ber of chronic diseases, renal impairment and
waist–hip ratio (in tertiles)] (Model 4). Separate
models were fitted to the entire and restricted
cohorts, first with sex as a confounder and sec-
ondly stratified by sex.
We examined the potential non-linear relation
between 25(OH)D (continuous) and all-cause mor-
tality nonparametrically with restricted cubic
splines [32] using SAS version 9.3 (SAS Institute
A. Granic et al. 25(OH)D and mortality
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Inc., Cary, NC, USA). The remaining analyses were
performed using IBM SPSS Statistics software
version 21 (IBM Corporation, Armonk, NY, USA).
Sensitivity analysis
We compared the survival data obtained from
analyses in which serum 25(OH)D was divided into
season-specific quartiles (i.e. ‘data driven’) with
results from the same models but in which 25(OH)
D was categorized by predefined cut-off values [13,
17] as follows: (i) <25 nmol L1 (severely deficient),
≥25 to <50 nmol L1 (deficient), 50–74 nmol L1
(insufficient) and ≥75 nmol L1 (sufficient) [17],
with two middle (collapsed) categories as the refer-
ent; and (ii) as suggested by the IOM [13]:
<30 nmol L1 (deficient), 30–50 nmol L1 (insuffi-
cient; referent) and >50 nmol L1 (sufficient). Addi-
tionally, the final Cox proportional hazards model
(Model 4) was further adjusted for the Fried frailty
status (robust/pre-frail/frail), which was available
for 552 participants (65.3%) [33]. We also assessed
mortality risk approximately 1 year after baseline
25(OH)D measurement and excluded 77 (9.1%)
participants who died before 1 January 2008.
Results
The baseline characteristics of all participants and
stratified by sex are shown in Table S3.
Compared with participants with successfully mea-
sured baseline 25(OH)D status (n = 775), thosewith
missing 25(OH)D data (n = 70; 8.3%) were more
likely to be women [v2(1) = 8.7, P = 0.003], to have
cognitive impairment [v2(1) = 6.7, P = 0.01] and to
be less physically active (U = 21 914.0, P < 0.001),
and were less likely to drink alcohol [v2(1) = 7.6,
P = 0.006]. Participants with 25(OH)D data were
more likely not to take any vitamin D-containing
supplements but to take other vitamins [v2(2) = 8.4,
P = 0.02].
All-cause mortality associated with season-specific 25(OH)D quartiles
At the end of follow-up (1 April 2012), approxi-
mately 6 years from baseline, 443 (52.4%) partic-
ipants were still alive, and the mean survival time
was 4.34 years (95% CI 4.20–4.48). Overall, 179
(58.9%) of 304 men with 25(OH)D status died
during follow-up compared with 229 (48.6%) of
471 women. Those who died were more likely to be
cognitively impaired at baseline (v2(1) = 51.1,
P < 0.001), to have renal impairment (v2(1) = 9.6,
P = 0.002), to smoke (v2(1) = 7.2, P = 0.03), not to
drink alcohol (v2(1) = 11.2, P = 0.001) and not to
take any vitamin supplements (v2(2) = 6.8,
P = 0.03), but to take prescribed vitamin D medi-
cation (v2(1) = 18.1, P < 0.001).
In the unadjusted model, we found a significant
association between 25(OH)D and survival in the
entire cohort (Mantel-Cox v2(2) = 7.90, P = 0.02),
with the longest survival time in the middle season-
specific group (SQ2 + SQ3: mean 4.51 years, 95%
CI 4.32–4.69) and the shortest survival in highest
group (SQ4: mean 4.12 years, 95% CI 3.84–4.41)
(Model 1). Differences between the middle and two
other 25(OH)D season-specific groups emerged
within the first year of mortality follow-up and
persisted until the last year (Fig. 1a).
This U-shaped relationship between survival and
25(OH)D remained after adjustment in a Cox
proportional hazards model for sociodemographic
variables (Table 1, left panel), with increased mor-
tality in the lowest (SQ1: HR 1.31, 95% CI 1.01–
1.69, P = 0.04) and the highest season-specific
quartiles (SQ4: HR 1.44, 95% CI 1.12–1.85,
P = 0.004) of 25(OH)D compared with the middle
combined (referent) quartiles (Model 2). The U-
shaped association disappeared after additional
adjustment for lifestyle factors (smoking, alcohol
intake and physical activity) with only participants
in the highest quartile being at increased risk of
mortality (SQ4: HR 1.37, 95% CI 1.06–1.77,
P = 0.02) compared with the reference group
(Model 3). This effect was further attenuated to a
nonsignificant trend when adjusted for mental
health and morbidity-related factors (SQ4: HR
1.25, 95% CI 0.97–1.63, P = 0.09; Model 4).
When the analyses were restricted to those not
taking vitamin D either as supplements or pre-
scribed medication (restricted cohort), and after
adjustment for sociodemographic variables (Model
2), shorter survival was evident only in the lowest
25(OH)D quartile (SQ1: HR 1.47, 95% CI 1.12–
1.91, P = 0.005), which was attenuated to a trend
(P = 0.06) after adjustment for lifestyle factors, and
abrogated in the fully adjusted model (Table 1,
right panel).
In unadjusted sex-stratified analyses of the entire
cohort, survival was longest in the middle season-
specific 25(OH)D group in women (mean
4.86 years, 95% CI 4.63–5.08; Mantel-Cox
v2(2) = 13.15, P = 0.001) but not in men (mean
A. Granic et al. 25(OH)D and mortality
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4.07 years, 95% CI 3.78–4.36; Mantel-Cox
v2(2) = 1.01, P = 0.6) (Fig. 1b,c). Similar results
were found in the fully adjusted model for the
entire cohort with a shorter survival in the highest
season-specific quartile (compared with the middle
referent quartiles) but again only in women (SQ4:
HR 1.51, 95% CI 1.06–2.14, P = 0.02; Model 4)
(Table 2, left panel). In the restricted cohort only,
women in the lowest season-specific quartile had
an increased risk of mortality (SQ1: HR 1.77, 95%
CI 1.19–2.64, P = 0.005) after adjusting for soci-
odemographic and lifestyle variables (Model 3),
which was attenuated but remained significant in
the fully adjusted model (SQ1: HR 1.63, 95% CI
1.07–2.49, P = 0.02; Model 4) (Table 2, right
panel). The finding that the association between
raised 25(OH)D concentration and increased mor-
tality was only observed in women, and further-
more was not found in the restricted cohort,
suggests that the increased mortality amongst all
participants in the highest season-specific 25(OH)
D quartile may be attributed to women taking
vitamin D-containing supplements/medication.
For the restricted cubic splines analysis, three,
four and five knots were fitted at percentiles with
three knots [at approximately 20, 40 and
60 nmol L1 25(OH)D] having a marginally better
fit as judged by the Akaike Information Criterion. A
non-linear dose–response relation between 25(OH)
D concentration and all-cause mortality was evi-
dent in the entire cohort (test for non-linear rela-
tion, P < 0.001; Fig. 2a) and in women (test for
non-linear relation, P < 0.001; Fig. 2b).
Sensitivity analyses
All-cause mortality associated with 25(OH)D prede-
fined cut-off values
In the entire 25(OH)D cohort, we detected a similar
U-shaped relationship between25(OH)Dand6-year
survival (Table S4), with both ‘severely deficient’
(<25 nmol L1) and ‘sufficient’ (≥75 nmol L1) 25
(OH)D concentration ranges [17] being associated
with increased risks of mortality (43% and 86%,
respectively), compared with the combined middle
concentration ranges after adjusting for season of
blood testing and sociodemographic confounders
(Model 2). Further adjustment for lifestyle and
mental health and morbidity-related variables
(Model 4) abolished the risk in those with concen-
trations <25 nmol L1 and reduced the risk in the
(a) (b) (c)
Fig. 1 Kaplan–Meier plot of the probability of survival by season-specific 25-hydroxyvitamin D [25(OH)D] groups. There
were statistically significant differences in survival across season-specific 25(OH)D groups (derived from season-specific
quartiles) over 6 years of mortality follow-up amongst participants in the Newcastle 85+ Study. Individuals in the middle
season-specific 25(OH)D group had a higher probability of survival compared with those in the two other groups (a). Survival
was significantly longer in women (b) but not men (c) in the middle season-specific 25(OH)D group compared with women
and men, respectively, in the two other groups.
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≥75 nmol L1 group to51% (P = 0.006).However, in
contrast to analyses with 25(OH)D categories
defined by season-specific quartiles, women but
not men with a concentration of 25(OH)
D ≥75 nmol L1 had significantly increasedmortal-
ity in the entire and restricted cohorts, even in the
fully adjusted models (Table S5).
Proportionality assumptions of 25(OH)D groups
were confirmed although inspection of log-minus-
log plots of all models. The results were unchanged
when models were fitted excluding imputed values
for covariates (data not shown).
We excluded participants who died within the first
year of mortality follow-up (by 1 January 2008) and
found similar results. In the fully adjusted model
(Model 4), increased mortality was observed among
women in the highest season-specific quartile
(SQ4: HR 1.56, 95% CI 1.06–2.30, P = 0.02) and
in those in the ≥75 nmol L1 group (HR 1.91, 95%
CI 1.25–2.91, P = 0.003) compared with the middle
groups. In the restricted cohort, women with a
concentration of 25(OH)D ≥75 nmol L1 had a 2.8-
fold increased risk of dying (data not shown).
In analyses in which the IOM cut-off values for 25
(OH)D status were used [13], the U-shaped rela-
tionship with all-cause mortality was not observed
(Tables S6 and S7). Women with a concentration of
25(OH)D >50 nmol L1 in the entire but not in the
restricted cohort had a 50% increased risk of
mortality (P = 0.03) after adjusting for season of
blood collection and sociodemographic variables
(Model 2), which remained raised (42% increased
risk) but was no longer significant in the fully
adjusted model (P = 0.07).
To explore the role of frailty in the association
between 25(OH) status and mortality, the final
model (Model 4) was additionally adjusted for the
Fried frailty status, with the covariate physical
activity excluded because of correlation and
overlap of concepts between the two variables.
Table 1 Hazard ratios (HRs) for all-cause mortality by season-specific serum 25-hydroxyvitamin D [25(OH)D] groups (derived
from season-specific quartiles) in the Newcastle 85+ Study
Model
Mortality in entire cohort
(ntotal = 775; ncases = 363)
Mortality in restricted cohorta
(ntotal = 625; ncases = 272)
25(OH)D groupb HR (95% CI) P value 25(OH)D group HR (95% CI) P value
Model 1 Lowest (ncases = 97) 1.33 (1.03–1.71) 0.03 Lowest (ncases = 96) 1.44 (1.11–1.87) 0.006
Middle (ncases = 166) 1 (reference) Middle (ncases = 139) 1 (reference)
Highest (ncases = 100) 1.36 (1.06–1.74) 0.02 Highest (ncases = 37) 1.02 (0.71–1.46) 0.93
Model 2 Lowest 1.31 (1.01–1.69) 0.04 Lowest 1.47 (1.12–1.91) 0.005
Middle 1 (reference) Middle 1 (reference)
Highest 1.44 (1.12–1.85) 0.004 Highest 1.04 (0.72–1.49) 0.85
Model 3 Lowest 1.15 (0.89–1.48) 0.30 Lowest 1.30 (0.99–1.70) 0.06
Middle 1 (reference) Middle 1 (reference)
Highest 1.37 (1.06–1.77) 0.02 Highest 1.11 (0.77–1.60) 0.57
Model 4 Lowest 1.10 (0.85–1.42) 0.48 Lowest 1.22 (0.93–1.60) 0.16
Middle 1 (reference) Middle 1 (reference)
Highest 1.25 (0.97–1.63) 0.09 Highest 1.05 (0.73–1.53) 0.79
Model 1 is unadjusted; Model 2 is adjusted for sociodemographic variables (sex, education, marital status and number of
income sources); Model 3 is additionally adjusted for lifestyle factors (smoking, alcohol intake and physical activity); Model
4 is additionally adjusted for mental health and morbidity-related variables [depressive symptoms, cognitive impairment
(≤25 points on the Standardized Mini Mental Status Examination), number of chronic diseases, renal impairment and
waist–hip ratio. The following missing values were imputed with the reference (ref) category: education (n = 11, ref: 12–
20 years), number of income sources (n = 5, ref: 4–5), marital status (n = 2, ref: married), physical activity (n = 6, ref:
high), smoking status (n = 2, ref: former smoker), alcohol intake (n = 4, ref: yes), depressive symptoms (n = 42, ref: no),
cognitive status at baseline (n = 2, ref: cognitively impaired), renal impairment (n = 1, ref: yes). ntotal, total number of
participants; ncases, number of deaths; CI, confidence interval.
aAnalyses were restricted to the cohort of individuals not
taking vitamin D supplements/prescribed medication. bMiddle two quartiles of season-specific serum 25(OH)D were
combined and served as the reference (see Supplementary Table 1 for details).
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Women belonging to the highest season-specific
quartile or ‘sufficient’ 25(OH)D category (i.e.
≥75 nmol L1) had an increased risk of mortality
compared with the corresponding (referent) group
(SQ4: HR 1.73, 95% CI 1.08–2.77, P = 0.02;
‘sufficient’ group: HR 2.22, 95% CI 1.32–3.75,
P = 0.003) (data not shown). This suggests that
higher concentrations of 25(OH)D may adversely
affect survival in women irrespective of their
frailty status.
Table 2 Hazard ratios (HRs) for all-cause mortality by season-specific serum 25-hydroxyvitamin D [25(OH)D] groups (derived
from season-specific quartiles) for men and women in the Newcastle 85+ Study
Model
25(OH)D groupa HR (95% CI) P value 25(OH)D group HR (95% CI) P value
Mortality in men
(entire cohort, ntotal = 304, ncases = 169)
Mortality in women
(entire cohort, ntotal = 471, ncases = 194)
Model 1 Lowest (ncases = 44) 1.20 (0.84–1.71) 0.33 Lowest (ncases = 53) 1.57 (1.10–2.25) 0.01
Middle (ncases = 95) 1 (reference) Middle (ncases = 71) 1 (reference)
Highest (ncases = 30) 1.10 (0.73–1.66) 0.64 Highest (ncases = 70) 1.78 (1.28–2.48) <0.001
Model 2 Lowest 1.10 (0.76–1.58) 0.63 Lowest 1.60 (1.12–2.29) 0.01
Middle 1 (reference) Middle 1 (reference)
Highest 1.08 (0.71–1.64) 0.73 Highest 1.87 (1.34–2.62) <0.001
Model 3 Lowest 0.96 (0.66–1.39) 0.82 Lowest 1.42 (0.99–2.04) 0.06
Middle 1 (reference) Middle 1 (reference)
Highest 1.13 (0.74–1.73) 0.56 Highest 1.59 (1.13–2.24) 0.008
Model 4 Lowest 0.95 (0.65–1.39) 0.79 Lowest 1.27 (0.87–1.84) 0.22
Middle 1 (reference) Middle 1 (reference)
Highest 1.06 (0.69–1.64) 0.78 Highest 1.51 (1.06–2.14) 0.02
Mortality in men
(restricted cohortb, ntotal = 276, ncases = 150)
Mortality in women
(restricted cohortb, ntotal = 349, ncases = 122)
Model 1 Lowest (ncases = 44) 1.24 (0.86–1.77) 0.25 Lowest (ncases = 52) 1.91 (1.30–2.81) 0.001
Middle (ncases = 88) 1 (reference) Middle (ncases = 51) 1 (reference)
Highest (ncases = 18) 0.81 (0.49–1.35) 0.42 Highest (ncases = 19) 1.38 (0.82–2.34) 0.23
Model 2 Lowest 1.15 (0.79–1.66) 0.47 Lowest 1.98 (1.34–2.93) 0.001
Middle 1 (reference) Middle 1 (reference)
Highest 0.79 (0.47–1.32) 0.37 Highest 1.37 (0.80–2.34) 0.25
Model 3 Lowest 1.01 (0.69–1.48) 0.95 Lowest 1.77 (1.19–2.64) 0.005
Middle 1 (reference) Middle 1 (reference)
Highest 0.90 (0.53–1.51) 0.68 Highest 1.37 (0.80–2.35) 0.26
Model 4 Lowest 0.95 (0.64–1.40) 0.78 Lowest 1.63 (1.07–2.49) 0.02
Middle 1 (reference) Middle 1 (reference)
Highest 0.90 (0.53–1.54) 0.71 Highest 1.32 (0.76–2.28) 0.32
Model 1 is unadjusted; Model 2 is adjusted for sociodemographic variables (education, marital status and number of income
sources);Model3isadditionallyadjustedforlifestylefactors(smoking,alcoholintakeandphysicalactivity);Model4isadditionally
adjusted for mental health and morbidity-related variables [depressive symptoms, cognitive impairment (≤25 points on the
Standardized Mini Mental Status Examination), number of chronic diseases, renal impairment and waist – 31 – hip ratio (in
tertiles)].Thefollowingmissingvalueswereimputedwiththereference(ref)category:education(n = 11,ref:12–20 years),number
of incomesources(n = 5,ref:4–5),maritalstatus(n = 2,ref:married),physicalactivity (n = 6,ref:high),smokingstatus(n = 2,ref:
former smoker), alcohol intake (n = 4, ref: yes), depressive symptoms (n = 42, ref: no), cognitive status at baseline (n = 2, ref:
cognitively impaired) and renal impairment (n = 1, ref: yes). ntotal, total number of participants; ncases, number of deaths; CI,
confidenceinterval.aMiddletwoquartilesofseason-specificserum25(OH)Dwerecombinedandservedasthereference.bAnalyses
were restricted to the cohort of individuals not taking vitaminDsupplements/prescribedmedication.
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Discussion
In this prospective cohort study of older adults
aged ≥85 years, we found a dose–response
relationship between serum 25(OH)D and all-cause
mortality, with both the lowest and highest season-
specific 25(OH)D quartiles being associated with
higher mortality over 6 years. The higher risk of
mortality amongst participants with the highest
concentrations [a threshold range of ≥47 nmol L1
(spring) to ≥69 nmol L1 (summer) for the highest
season-specific quartile] appeared to be driven
largely by women taking vitamin D-containing
supplements and/or prescribed medication. Using
25(OH)D as a continuous covariate and fitting with
restricted cubic splines confirmed the relationship
between 25(OH)D and mortality. Moreover, in sen-
sitivity analyses using predefined 25(OH)D cut-off
values [17], the highest (≥75 nmol L1) ‘sufficient’
concentration was still associated with an
increased risk of mortality amongst women who
were not using vitamin D supplements/medica-
tion, suggesting that at this concentration the risk
of reduced survival is not solely due to supplemen-
tation. These results remained when we excluded
participants who died within the first year of follow-
up to control for the possibility that poor health
and reduced mobility close to the time of death
affected 25(OH)D status. Furthermore, the greater
risk of mortality amongst women with the highest
25(OH)D concentrations (SQ4 or ‘sufficient’ cate-
gories) was independent of their frailty status [34].
To our knowledge, this is the first observational
study to suggest a U-shaped relationship between
serum 25(OH)D and all-cause mortality in very old
adults. Several recent systematic reviews and
meta-analyses of prospective cohort studies inves-
tigating the association between 25(OH)D status
and risk of mortality [27, 28, 35, 36] have demon-
strated a shorter survival amongst adults with the
lowest (<25 or <50 nmol L1) compared with high-
est 25(OH)D concentrations, especially in those
aged 65 years and older [27, 36]. In other studies, a
non-linear relationship was noted with favourable
survival outcomes at concentrations between 50
and 90 nmol L1 [9–11]. However, except for the
study conducted in Israel [11], relatively few par-
ticipants aged over 85 years were included in these
studies.
Our findings are in general agreement with those of
a large retrospective study from general practices
in Copenhagen (CopD Study) [10] showing an
inverse J-shaped relationship between 25(OH)D
and mortality, with the longest survival at concen-
trations of 50–60 nmol L1 during 3 years of
follow-up. Similarly, a historical prospective study
of more than 420 000 members of the Clalit Health
(a)
(b)
Fig. 2 Restricted cubic spline curves of dose–response
relationship between serum 25-hydroxyvitamin D [25(OH)
D] and all-cause mortality in the Newcastle 85+ Study. A
non-linear dose–response relation was observed in the
entire cohort (a) and in women (b) using restricted cubic
splines with three knots fitted at percentiles (at approxi-
mately 20, 40 and 60 nmol L1) (test for non-linear
relation, P < 0.001).
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Services in Israel [11], which included >20 000
participants aged ≥85 years, found that the lowest
risk of mortality and acute coronary syndrome was
associated with 25(OH)D in the range of 20–
36 ng mL1 (50–90 nmol L1) during 4.5 years of
follow-up. A meta-analysis of 14 prospective cohort
studies involving the general population (age range
45–80 years and 1.3–27.0 years of follow-up) also
suggested a non-linear relationship between 25
(OH)D and mortality, but 25(OH)D levels of ~75–
87.5 nmol L1 were considered optimal [35].
We observed statistically significant sex differences
in mean (SD) 25(OH)D concentration which were
lower than recommended (i.e. below 50 nmol L1)
for optimal bone health in both men and women
[13], especially in our restricted cohort [38.48
(21.39) nmol L1]. The intake of vitamin D supple-
ments/medication is an important biological deter-
minant of 25(OH)D status in this cohort [23, 24],
and therefore we included intake of supplements/
medication and as potential confounders. The
higher mortality rates observed amongst very old
women, with higher 25(OH)D concentrations [SQ4
or ‘sufficient’ (≥75 nmol L1) categories] whether
users or nonusers of vitamin D supplements/
medication, respectively, have not been reported
previously [20–24]. The Women’s Health Initiative
calcium/vitamin D RCT, a 7-year combined ther-
apy intervention (1 g calcium and 400 IU vitamin D
daily), reported a trend towards mortality reduction
amongst postmenopausal women aged <70 years,
but neither a beneficial nor an adverse effect in
women aged >70 years [22]. The latest meta-analy-
sis of 56 RCTs of vitamin D supplementation and
survival [24] demonstrated a decrease in all-cause
mortality amongst predominantly older adults
including women aged ≥70 years, but also found
adverse renal outcomes associated with vitamin D3
and calcium combination therapy.
Lower (<37.5 nmol L1) and higher (≥75 nmol L1)
concentrations of 25(OH)D have been moderately
associated with frailty amongst older women (aged
≥69 years) in the Study of Osteoporotic Fractures
[34], and the risk of death was significantly
increased amongst frail NHANES III participants
(aged ≥60 years) in the lowest (<49.5 nmol L1)
compared with not frail participants in the highest
(>84.1 nmol L1) 25(OH)D quartiles [37]. In the
present study, those in the middle 25(OH)D quar-
tiles/groups were least likely to be frail (P < 0.001);
however, the increased risk of mortality in women
in the lowest and highest 25(OH)D groups was
independent of their frailty status and was not
affected by exclusion of those who died within first
year of follow-up. Compared with men, women
were more likely to have osteoporosis (P < 0.001)
and to be treated with prescribed vitamin D med-
ication (P < 0.001), which included calcium com-
bination therapy (Table S2). Because the duration
and dosage of the therapy was not known, we
cannot exclude any potential adverse effects of co-
supplementation, or the possibility that the higher
mortality amongst individuals taking vitamin D
supplements/medication and with a level of 25
(OH)D ≥75 nmol L1 could be driven partly by
those with a prior long-standing vitamin D defi-
ciency corrected recently by supplementation.
The results from observational cohort studies
exploring sex differences in mortality in relation
to 25(OH)D are inconclusive and have not included
the very old. The NHANES III showed a U-shaped
relationship between 25(OH)D levels and mortality
in the general population of women (aged
≥20 years) but not in men at concentrations of
<50 and >125 nmol L1 [12]. In a study of older
men (a birth cohort from 1920 to 1924, aged 71 at
baseline) from the Uppsala region, an increased
risk of total and cancer mortality was observed at
both low (<46 nmol L1) and high (>98 nmol L1)
25(OH)D concentrations over 12.7 years of follow-
up [7]. In both these studies, the longest survival
was associated with the middle 25(OH)D catego-
ries, but the thresholds were much higher than in
the present study (NHANES III: 75–100 nmol L1;
Uppsala Study of Older Men: 46–98 nmol L1); this
difference may be related to the age of participants,
habitual diet, supplementation, length of follow-up
or other factors/covariates.
Several limitations of our study should be noted.
There remains the possibility of residual confound-
ing by additional factors that affect the relationship
between serum 25(OH)D and mortality. On the
other hand, having a large number of variables in a
fully adjusted model (Model 4) may have contrib-
uted to a nonsignificant or biased result, given the
fact that we categorized 25(OH) into season-spe-
cific quartiles (naverage - mean number per quar-
tile = 194), and therefore may have had limited
power for detection of associations. Although we
controlled for the number of chronic diseases and
for frailty status, increased mortality amongst
older women may be mediated by other mecha-
nisms associated with nonoptimal 25(OH)D
levels such as polypharmacy [38] or an acute
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inflammatory response [39, 40]. Recent studies
have demonstrated a rapid decline in serum 25
(OH)D after elective hip or knee surgery or after an
acute inflammatory insult, thus 25(OH)D may be
an unreliable biomarker of vitamin D status up to
3 months after the event [39, 40]. Although using
quartiles of 25(OH)D may limit the impact of
hazard risks, we confirmed the U-shaped relation-
ship between 25(OH)D and mortality using prede-
fined cut-off values [17] and restricted cubic
splines. Whilst recognizing that there is seasonal
variations in 25(OH)D status, the results were
based on a single measurement, which may mis-
classify 25(OH)D levels throughout the year. Addi-
tionally, lower values of 25(OH)D in the present
study could be due to the choice of assay (DiaSo-
rin), which has been reported to provide lower
readings compared with other methods (e.g. liquid
chromatography tandem-mass spectrometry) [41],
and to overestimate vitamin D deficiency/insuffi-
ciency (<30 nmol L1/<50 nmol L1, respectively),
especially in older women aged ≥65 years [42]. We
used physical activity as a proxy for exposure to
ultraviolet-B radiation, a major source of circulat-
ing 25(OH)D, and did not control for dosage or
duration of exposure for vitamin D supplements/
medication, or for their potential interaction with
other medication [38]. Whether or not there was
any long-standing vitamin D deficiency amongst
women with the highest 25(OH)D concentrations,
which may have been corrected by supplementa-
tion prior to baseline, was unknown. The results
from this study may be generalized to elderly white
populations (aged ≥85 years) living at similar lati-
tudes. We did not explore disease-specific mortality
in relation to 25(OH)D because of high rates of
multimorbidity in this age group [30].
The strengths of our study include: (i) the homog-
enous age of the cohort; (ii) the prospective 6-year
follow-up; (iii) inclusion of several mortality-related
covariates in both the entire and restricted cohorts;
(iv) analyses stratified by sex and exposure (i.e.
intake of vitamin D supplements/medication) and
(v) use of ‘data driven’ season-specific 25(OH)D cut-
off values as the preferred method of adjusting for
seasonal variability in vitamin D status [43].
In summary, both low and high concentrations of
25(OH)D were associated with an increased risk of
all-cause mortality amongst very old adults, espe-
cially amongst women who reported taking vitamin
D-containing supplements and prescribed medica-
tion as well as in women with concentrations
≥75 nmol L1 irrespective of intake of supple-
ments/medication. Future recommendations for
optimal concentrations of serum 25(OH)D should
pay special attention to the very old, to prevent
problems related to over-treatment in this age
group [13, 18, 25, 26].
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